Drug Discovery market research reports by DelveInsight

• Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors - Pipeline Insight, 2024 Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors Overview ""Anti-PD-1 / Anti-PD-L1 Refractory Solid Tumors Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and ... Read More

• Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2024 “Apolipoprotein B (ApoB) Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Apolipoprotein B (ApoB) Inhibitor develop ... Read More

• Arginine Depletors - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Arginine Depletors - Pipeline Insight, 2024 “Arginine Depletors - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Arginine Depletors development. The report provides detailed coverage o ... Read More

• Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2024 DelveInsight’s, “Type 4 Cyclic Nucleotide Phosphodiesterase Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Type 4 Cyclic Nucleotide Phosphodiester ... Read More

• Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Idiopathic CD4+ Lymphocytopenia - Pipeline Insight, 2024 Idiopathic CD4+ Lymphocytopenia Overview ""Idiopathic CD4+ Lymphocytopenia Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Idiopathic CD4+ ... Read More

• Idiopathic Short Stature - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Idiopathic Short Stature - Pipeline Insight, 2024 Idiopathic Short Stature Overview ""Idiopathic Short Stature Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Idiopathic Short Stature market. A de ... Read More

• Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2024 DelveInsight’s, “Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape. It covers the pipeline drug ... Read More

• Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 3,000

  Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2024 DelveInsight’s, “Idiopathic Pulmonary Fibrosis - Pipeline Insight, 2024” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles ... Read More

• Syphilis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Syphilis - Pipeline Insight, 2024 Syphilis Overview ""Syphilis Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Syphilis market. A detailed picture of the Syphilis pipeline landscape is provided, w ... Read More

• Multiple sclerosis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 3,000

  Multiple sclerosis - Pipeline Insight, 2024 DelveInsight’s, “Multiple sclerosis - Pipeline Insight, 2024,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and noncli ... Read More

• Tuberous Sclerosis- Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Tuberous Sclerosis- Pipeline Insight, 2024 DelveInsight’s, “Tuberous Sclerosis- Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Tuberous Sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinica ... Read More

• Selective COX-2 Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Selective COX-2 Inhibitor - Pipeline Insight, 2024 “Selective COX-2 Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Selective COX-2 Inhibitor development. The report provide ... Read More

• Sensory Neuropathy - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Sensory Neuropathy - Pipeline Insight, 2024 Sensory Neuropathy Overview ""Sensory Neuropathy Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sensory Neuropathy market. A detailed picture of the Se ... Read More

• Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insight, 2024 Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Overview ""Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insig ... Read More

• Severe Keratitis - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Severe Keratitis - Pipeline Insight, 2024 Severe Keratitis Overview ""Severe Keratitis Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Severe Keratitis market. A detailed picture of the Severe Ker ... Read More

• Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024 DelveInsight’s, “Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024” report provides comprehensive insights about 8+ companies and 10 pipeline drugs in Interleukin-2 (IL-2) Inhibitor pipeline landscape. It covers the pipeline drug profile ... Read More

• Cutaneous Lupus Erythematosus – Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,500

  Cutaneous Lupus Erythematosus – Pipeline Insight, 2024 DelveInsight’s, “Cutaneous Lupus Erythematosus – Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the pipeline drug profiles ... Read More

• 11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2024 “11 Beta-Hydroxysteroid Dehydrogenase Type 1 (11ßHSD1) Inhibitor - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growt ... Read More

• Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Complicated skin and soft tissue infections (cSSTI) - Pipeline Insight, 2024 DelveInsight’s, “Complicated Skin and Soft Tissue Infections (cSSTI) - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complicated Skin and Soft Tissue Infections ... Read More

• Uremic Pruritus and Associated Dry Skin - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Uremic Pruritus and Associated Dry Skin - Pipeline Insight, 2024 Uremic Pruritus and Associated Dry Skin Overview ""Uremic Pruritus and Associated Dry Skin Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects acr ... Read More

• 22q11.2 Deletion Syndrome - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  22q11.2 Deletion Syndrome - Pipeline Insight, 2024 22q11.2 Deletion Syndrome Overview ""22q11.2 Deletion Syndrome Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the 22q11.2 Deletion Syndrome market. ... Read More

• Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 2,000

  Undifferentiated Pleomorphic Sarcoma (UPS) - Pipeline Insight, 2024 Undifferentiated Pleomorphic Sarcoma (UPS) Overview ""Undifferentiated Pleomorphic Sarcoma (UPS) Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth pros ... Read More

• 5-HT1B Antagonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  5-HT1B Antagonist - Pipeline Insight, 2024 “5-HT1B Antagonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1B Antagonist development. The report provides detailed coverage of t ... Read More

• Toll-Like Receptor Agonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Toll-Like Receptor Agonist - Pipeline Insight, 2024 “Toll-Like Receptor Agonist - Pipeline Insight, 2024” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Toll-Like Receptor Agonist development. The report prov ... Read More

• Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2024

  Apr 01, 2024  |  Published by: DelveInsight  |  USD 1,250

  Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2024 “Transient Receptor Potential Vanilloid 1 (TRPV-1) Receptor (Capsaicin Receptor or Vanilloid Receptor 1) Agonist - Pipeline Insight, 2024” report by DelveInsight o ... Read More

< prev 44 45 46 47 48 49 50 next >